In addition to that, we are exploring and expanding immunotherapy to attempt to improve the outcomes. In the next 5 years, there will be combinations of different regimens to improve the overall outcomes of our patients.
Is there anything else that you would like to add?
We spoke about neoadjuvant chemotherapy and its potential role in that subpopulation of patients who have marginally resectable pancreas cancer. The potential role of radiation therapy is a way to control the disease locally in order for the tumor to become resectable or have the initial landmark to be margin negative. That is what we call R0 resections, which is an important initial step.